Lipid management remains a cornerstone of secondary prevention in atherosclerotic cardiovascular disease (ASCVD), with increasingly strong evidence supporting its central role across all vascular territories, including coronary, cerebrovascular, and peripheral arterial beds. The 2024 ACC/AHA/Multisociety Guideline for the Management of Lower Extremity Peripheral Artery Disease (PAD) and the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia collectively represent a major paradigm shift toward more aggressive, unified, and prevention-driven lipid-lowering strategies.^1-3 From a vascular medicine perspective, where clinicians routinely manage patients with systemic atherosclerosis, these updates are transformative.

The 2024 PAD guideline reinforces high-intensity statin therapy as the foundation of treatment for all patients with PAD (Class 1, Level of Evidence [LOE] A), targeting a ≥50% reduction in low-density lipoprotein cholesterol (LDL-C).¹ Importantly, this recommendation extends beyond cardiovascular event reduction, recognizing that statins significantly reduce major adverse limb events (MALE), including amputation and acute limb ischemia.^1,4 This dual benefit is particularly relevant in vascular practice, where limb outcomes are as clinically meaningful as cardiovascular outcomes or in patients who cannot tolerate statins. For patients with a persistent LDL-C level ≥70 mg/dL despite maximally tolerated statin therapy, addition of nonstatin agents—either ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors—is recommended (Class 2a, LOE B-R).¹ Evidence from randomized controlled trials confirms that intensified lipid lowering reduces MALE and major adverse cardiovascular events (MACE), reinforcing lipid management as a core limb-preserving strategy in PAD.^1-5

Moreover, the 2026 dyslipidemia guideline marks a fundamental shift in lipid management strategy by reintroducing explicit LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) targets, moving beyond the prior exclusive reliance on percentage reduction.² For instance, for patients with very high-risk ASCVD, a category that includes most patients with symptomatic PAD and other established vascular disease, the recommended LDL-C target is <55 mg/dL and non-HDL-C <85 mg/dL.² In contrast, for patients with ASCVD not classified as very high risk, an LDL-C level <70 mg/dL is recommended.² This transition to absolute targets is particularly important in vascular medicine. In real-world practice, vascular specialists manage a disproportionately high number of patients with disease in multiple vascular beds, meaning that most patients seen in vascular clinics now fall into the very high-risk category and therefore require LDL-C lowering to <55 mg/dL. This represents a substantial intensification compared with prior guidelines and highlights the importance of proactive lipid optimization in all vascular patients.

The 2026 dyslipidemia guideline also introduces a unified ASCVD framework across coronary, carotid, peripheral, and aortic vascular beds, reflecting a paradigm shift toward recognizing atherosclerosis as a systemic, polyvascular disease rather than organ-specific entities.² This approach is consistent with contemporary vascular practice, where polyvascular disease is common. From a preventive standpoint, PAD and carotid artery disease are redefined as systemic atherosclerotic manifestations warranting intensification of lipid-lowering therapy equivalent to coronary artery disease. This integration reinforces the evolving role of vascular specialists as comprehensive cardiovascular prevention providers.

This framework is strongly supported by expanding evidence consistently demonstrating that "lower for longer is better" for LDL-C across the entire spectrum of ASCVD. The Ez-PAVE (Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease — Randomized Comparison of LDL Cholesterol Targeting <70 mg/dL vs. <55 mg/dL) trial provides direct clinical validation of this principle, showing that targeting LDL-C <55 mg/dL is superior to <70 mg/dL in reducing recurrent cardiovascular events among patients with established ASCVD, including those with PAD and carotid artery disease.⁶

Complementing this evidence, major randomized trials and subgroup analyses have further demonstrated that intensive lipid lowering confers benefits beyond traditional cardiovascular endpoints. PCSK9 inhibitor trials, including the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial, have shown significant reductions in MALE, including acute limb ischemia and major amputation.⁴ Similarly, statin therapy has been associated with approximately 30% reductions in MALE and up to 35% reductions in amputation risk.^1,4 Collectively, these data highlight a critical and often under-recognized principle in vascular medicine: Lipid lowering is not only cardioprotective but also limb-protective, reinforcing its central role in comprehensive vascular care.

Building on this evidence, the 2026 guideline also expands and simplifies access to nonstatin therapies. Unlike earlier recommendations that mandated a stepwise sequence of statin followed by ezetimibe and then PCSK9 inhibitors, the current framework allows clinicians to select among ezetimibe, PCSK9 inhibitors, and bempedoic acid, based on the magnitude of LDL-C reduction required and patient-specific factors.² This flexibility is particularly important in vascular practice, where patients frequently present with advanced or polyvascular disease and therefore require substantial LDL-C reductions to reach guideline-directed targets. Given that PCSK9 inhibitors can achieve approximately 60% LDL-C reduction compared with 15-20% for ezetimibe, early combination therapy is often necessary in patients with PAD or polyvascular ASCVD.^2,7

From a broader vascular perspective, these updates represent a shift in preventive care. Vascular specialists routinely manage patients at the highest end of ASCVD risk, many of whom already have established limb ischemia, carotid stenosis, or diffuse atherosclerosis involving multiple vascular beds. In this context, lipid management is central to preventing disease progression, recurrent ischemic events, and long-term morbidity. Therefore, aggressive optimization of modifiable risk factors, particularly LDL-C reduction, represents one of the most impactful long-term strategies available in vascular medicine. Adherence to the 2026 dyslipidemia guideline should thus be viewed not merely as compliance with updated recommendations, but as a meaningful opportunity to transform patient outcomes, with potential reductions in amputations, strokes, myocardial infarction, and repeat revascularization procedures.

In patients with PAD or carotid artery disease, optimal implementation of contemporary lipid guidelines begins with immediate initiation of high-intensity statin therapy, followed by timely reassessment of lipid parameters to ensure early trajectory toward goal attainment. When LDL-C remains above 55 mg/dL, escalation of therapy with ezetimibe and/or PCSK9 inhibition should be implemented without delay or adherence to unnecessary stepwise sequencing, reflecting the contemporary paradigm of rapid, goal-directed lipid optimization.² Adjunctive tools, including the PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) risk equations, lipoprotein(a) measurement, and apolipoprotein B assessment, further refine global risk stratification and allow for a more granular assessment of residual risk in select patients.²

In conclusion, the 2024 PAD and 2026 dyslipidemia guidelines collectively redefine lipid management as a unified, aggressive, and prevention-focused strategy across all vascular beds.^1,2 For vascular specialists, these advances provide a critical opportunity to translate evidence into meaningful reductions in MACE and MALE. The 2026 guideline further expands the therapeutic options by elevating bempedoic acid to a first-line nonstatin option based on CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) trial data demonstrating cardiovascular benefit, while positioning inclisiran as a valuable alternative for select patients requiring durable LDL-C lowering with infrequent dosing.² In this framework, lipid management is one of the most powerful disease-modifying interventions in contemporary preventive vascular medicine.

References

1. Writing Committee Members, Gornik HL, Aronow HD, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(24):2497-2604. doi:10.1016/j.jacc.2024.02.013
2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
3. Das SR, Bonaca MP, Creager MA, et al. Management of peripheral artery disease in adults with diabetes: 2025 ACC scientific statement: a report of the American College of Cardiology. J Am Coll Cardiol. Published online December 17, 2025. doi:10.1016/j.jacc.2025.11.027
4. McDermott MM. Peripheral artery disease in the legs. N Engl J Med. 2026;394(5):486-496. doi:10.1056/NEJMcp2501200
5. Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-350. doi:10.1161/CIRCULATIONAHA.117.032235
6. Lee YJ, Lee SJ, Kim JW, et al. Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease. N Engl J Med. 2026;394(14):1365-1375. doi:10.1056/NEJMoa2600283
7. Polonsky TS, McDermott MM. Lower extremity peripheral artery disease without chronic limb-threatening ischemia: a review. JAMA. 2021;325(21):2188-2198. doi:10.1001/jama.2021.2126